

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7562805

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AVISTA PHARMA SOLUTIONS, INC.	08/05/2020
RECEIVING PARTY DATA	
Name:	FENNEC PHARMACEUTICALS, INC.
Street Address:	68 TW ALEXANDER DRIVE
City:	RESEARCH TRIANGLE PARK
State/Country:	NORTH CAROLINA
Postal Code:	27709
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17849477
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6786941262
Email:	docket@kipsllc.com
Correspondent Name:	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC
Address Line 1:	400 PERIMETER CENTER TERRACE
Address Line 2:	SUITE 200
Address Line 4:	ATLANTA, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	21111-006US4
NAME OF SUBMITTER:	BRENT R. BELLOWS
SIGNATURE:	/BRENT R. BELLOWS/
DATE SIGNED:	09/28/2022
Total Attachments: 2	
source=21111-006US4_EXECUTED_Assignment_Avista_to_Fennec#page1.tif	
source=21111-006US4_EXECUTED_Assignment_Avista_to_Fennec#page2.tif	

ASSIGNMENT

WHEREAS, Avista Pharma Solutions, Inc., (hereinafter "Assignor") with a place of business at 3501 Tricenter Blvd, Suite C, Durham, NC 27713, is the present owner of the intellectual property rights set forth as follows:

- (1) United States provisional patent application bearing Application No. 62/693,502, filed on July 3, 2018;
- (2) United States provisional patent application bearing Application No. 62/693,503, filed on July 3, 2018;
- (3) United States non-provisional patent application bearing Application No. 16/458,261, filed on July 1, 2019;
- (4) United States non-provisional patent application bearing Application No. 16/458,267, filed on July 1, 2019;
- (5) International Patent Application No. PCT/US2019/040051, designating the United States and filed on July 1, 2019; and
- (6) International Patent Application No. PCT/US2019/040052, designating the United States and filed on July 1, 2019;

AND WHEREAS, Fennec Pharmaceuticals, Inc., having an office and place of business in 68 TW Alexander Drive, Research Triangle Park, NC 27709 (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said intellectual property rights;

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, Assignor has sold, assigned, set over, and transferred, and by these presents does sell, assign, set over and transfer unto said Assignee, its successors or assigns, the entire right, title and interest and the right to file applications for all countries in and to all inventions and improvements disclosed in the intellectual property rights, and in and to the said intellectual property rights, all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patent which may be granted therefrom, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for Letters Patent on the said inventions and improvements, including an assignment of all rights under the provisions of the International Convention, and all Letters Patent of foreign countries which may be granted therefrom; and Assignor does hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid intellectual property rights to the said Assignee as the assignee of the entire right, title and interest in and to the same, for the use of the said Assignee, its successors and assigns;

AND, for the consideration aforesaid, Assignor does hereby agree that Assignor and its executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to it relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to the said intellectual property rights hereby sold, assigned and conveyed, or intended so to be.

AND, furthermore, Assignor covenants and agrees with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by Assignor and that full right to convey the same as herein expressed is possessed by Assignor.

IN TESTIMONY WHEREOF, I have hereunto set my hand this 5th day of August, 2020.

Avista Pharma Solutions, Inc.

By: *Samantha Hanley*
(signature)

Name: Samantha Hanley
(print name)

Title: Vice President & Secretary

IN TESTIMONY WHEREOF, I have hereunto set my hand this 5th day of August 2020.

Fennec Pharmaceuticals, Inc.

By: *Robert Andrade*
(signature)

Name: Robert Andrade
(print name)

Title: Chief Financial Officer